Development of a preliminary composite disease activity index in psoriatic arthritis.
Authors
Mumtaz, AizadGallagher, Phil
Kirby, Brian
Waxman, Robin
Coates, Laura C
Veale J, Douglas
Helliwell, Philip
FitzGerald, Oliver
Affiliation
Department of Rheumatology, St Vincent's University Hospital, University College , Dublin, Dublin, Ireland.Issue Date
2012-02-01T10:32:48ZMeSH
AdultAged
Antirheumatic Agents/therapeutic use
Arthritis, Psoriatic/*diagnosis/drug therapy
Drug Monitoring/methods
Epidemiologic Methods
Female
Humans
Male
Middle Aged
Psoriasis/diagnosis/drug therapy
Quality of Life
*Severity of Illness Index
Treatment Outcome
Metadata
Show full item recordCitation
Ann Rheum Dis. 2011 Feb;70(2):272-7. Epub 2010 Nov 29.Journal
Annals of the rheumatic diseasesDOI
10.1136/ard.2010.129379PubMed ID
21115550Abstract
OBJECTIVES: To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis. METHODS: Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0-15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated. RESULTS: Significant correlation was seen between CPDAI and both patient (r = 0.834) and physician (r = 0.825) global disease activity assessments (p = 0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5. CONCLUSION: CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.Language
engISSN
1468-2060 (Electronic)0003-4967 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1136/ard.2010.129379
Scopus Count
Collections
Related articles
- Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
- Authors: Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B
- Issue date: 2011 May
- Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
- Authors: FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, Nab H, Molta C
- Issue date: 2012 Mar
- Early psoriatic arthritis.
- Authors: Gladman DD
- Issue date: 2012 May
- Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response.
- Authors: Helliwell PS, FitzGerald O, Fransen J
- Issue date: 2014 Jun
- Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
- Authors: Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS
- Issue date: 2010 Aug